NMTC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeuroOne Medical Technologies Corp (NMTC) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is deteriorating significantly, with revenue, net income, EPS, and gross margin all showing sharp declines. While the technical indicators are neutral and there are no strong positive catalysts or trading signals, the stock's high volatility and lack of recent news or congressional trading activity make it a risky choice. Analysts have a positive long-term outlook with a $1.50 price target, but the stock's current fundamentals and lack of momentum do not align with the user's investment profile.
The MACD is slightly positive at 0.0021, indicating weak upward momentum. RSI is neutral at 49.995, and moving averages are converging, suggesting no clear trend. Key support levels are at 0.711 and 0.683, with resistance at 0.802 and 0.83. The stock is trading near its pivot point of 0.757, showing limited directional bias.
Analyst Justin Walsh from JonesResearch initiated coverage with a Buy rating and a $1.50 price target, citing the company's portfolio of FDA-cleared products and support from Zimmer Biomet as growth drivers.
The company's financial performance is severely declining, with revenue down 53.90% YoY, net income down 180.54% YoY, and gross margin down 30.98% YoY. Additionally, there is no recent news, congressional trading data, or significant insider or hedge fund activity to support a positive outlook.
In Q1 2026, NeuroOne Medical Technologies reported a revenue decline of 53.90% YoY to $2,892,635. Net income dropped 180.54% YoY to -$1,437,890, and EPS fell 150.00% YoY to -0.03. Gross margin also decreased by 30.98% YoY to 54.2%.
Analyst Justin Walsh from JonesResearch initiated coverage on March 2, 2026, with a Buy rating and a $1.50 price target, citing the company's FDA-cleared products and distribution partnership with Zimmer Biomet as key growth drivers.
